More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$3.46B
EPS
-4.15
P/E ratio
--
Price to sales
--
Dividend yield
--
Beta
0.683895
Previous close
$29.33
Today's open
$29.57
Day's range
$29.38 - $30.18
52 week range
$22.96 - $43.15
show more
CEO
Brian Lian
Employees
53
Headquarters
San Diego, CA
Exchange
NASDAQ Capital Market
Shares outstanding
116105643
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Viking Therapeutics, Inc. (VKTX) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Viking Therapeutics, Inc. (VKTX) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Seeking Alpha • 20 hours ago

Viking Therapeutics, Inc. (VKTX) Exceeds Market Returns: Some Facts to Consider
The latest trading day saw Viking Therapeutics, Inc. (VKTX) settling at $29.78, representing a +1.53% change from its previous close.
Zacks Investment Research • 17 hours ago

Bull vs. Bear: The Quick Take on Viking Therapeutics Stock
Eli Lilly and Novo Nordisk are much larger companies and already have oral weight loss pills on the market. Investors are hoping Viking's VK2735 will prove efficacious and safe in its Phase 3 clinical trials.
The Motley Fool • Jun 3, 2026

1 Sector Warren Buffett and Greg Abel Are Largely Ignoring -- and Why Investors Shouldn't
Buffett, as CEO of Berkshire Hathaway, delivered six decades of market-beating returns. Abel took over the CEO role in January and aims to follow the path traced by the investing giant.
The Motley Fool • Jun 3, 2026

Viking Therapeutics' Q3 Catalyst That Could Turn Eli Lilly's and Novo Nordisk's Daily Weight Loss Pill Strategy Upside Down
VK2735 is being developed in both subcutaneous and oral forms, and upcoming Phase 1 maintenance trial results are a major catalyst. VK2735 may offer efficacy advantages over competitors' oral drugs.
The Motley Fool • Jun 2, 2026

Why Is Viking Therapeutics (VKTX) Up 3.2% Since Last Earnings Report?
Viking Therapeutics (VKTX) reported earnings 30 days ago. What's next for the stock?
Zacks Investment Research • May 29, 2026

If Viking Therapeutics Is Acquired, Here's Who Wins
Viking Therapeutics (VKTX) is the most closely watched biotech acquisition target. A buyer such as Eli Lilly (LLY) would benefit, as would Viking shareholders, and at least one GLP-1 competitor.
24/7 Wall Street • May 26, 2026

Prediction: These 2 Obesity Drug Stocks Could Double in 2026
The weight loss opportunity is a significant one for companies and investors -- and companies involved have seen their shares soar. Analysts predict the market will reach almost $100 billion within a few years.
The Motley Fool • May 26, 2026

Don't Buy Viking Therapeutics Stock Until You Read This
Enthusiasm for Viking Therapeutics and its weight-loss candidate has come and gone, and for good reason. While Viking is still trying to bring its first candidate to market, rivals are already increasing the competition with new product launches.
The Motley Fool • May 26, 2026

Is Viking Therapeutics a Top Takeover Target?
Big pharma still needs additional late-stage obesity drug assets. Viking's obesity pipeline could attract major pharmaceutical acquisition interest.
The Motley Fool • May 23, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Viking Therapeutics Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.